Andrographolide
Cat.No:IA0360 Solarbio
CAS:5508-58-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
NF-κB >
AndrographolideCAS:5508-58-7
Storage:Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year
Purity:HPLC≥98%
Appearance:White to off-white Solid
Qty:
Size:
CAS | 5508-58-7 |
Name | Andrographolide |
Molecular Formula | C20H30O5 |
Molecular Weight | 350.45 |
Solubility | Soluble in DMSO |
Purity | HPLC≥98% |
Appearance | White to off-white Solid |
Storage | Powder:2-8℃,2 years;Insolvent(Mother Liquid):-20℃,6 months;-80℃,1 year |
EC | EINECS 226-852-5 |
MDL | MFCD07778082 |
SMILES | O=C1OC[C@@H](O)/C1=C\C[C@@H]2C(CC[C@]3([H])[C@](C)(CO)[C@H](O)CC[C@@]23C)=C |
InChIKey | BOJKULTULYSRAS-OTESTREVSA-N |
InChI | InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1 |
PubChem CID | 5318517 |
Target Point | NF-kB |
Passage | NF-κB |
Background | Andrographolide is an NF-κB inhibitor that inhibits NF-κB activation by covalently modifying the cysteine residue of p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. |
Biological Activity | Andrographolide 是一种 NF-κB 抑制剂,通过共价修饰内皮细胞中 p50 的半胱氨酸残基而抑制 NF-κB 活化,而不影响 IκBα 降解或 p50/p65 核易位。[1] |
In Vitro | 穿心莲内酯(AP)浓度依赖性地抑制核因子κB配体(RANKL)介导的破骨细胞分化和体外骨吸收的受体活化剂,并降低破骨细胞特异性标记物的表达。穿心莲内酯通过共价修饰p50的还原Cys62而抑制TNFα诱导的NF-κB活化,从而减弱炎症,而不影响IκBα降解或p50/p65核转位。穿心莲内酯还抑制ERK/MAPK信号传导途径而不影响p38或JNK信号传导。穿心莲内酯以浓度依赖性方式抑制RAW 264.7细胞的破骨细胞分化。在BMM和RAW 264.7细胞中,穿心莲内酯以浓度依赖性方式抑制破骨细胞形成而没有任何明显的细胞毒性作用。穿心莲内酯治疗大大减少了骨吸收面积。在用2.5μM穿心莲内酯处理后,在对照组中仅观察到约30%的骨吸收。用10μM穿心莲内酯处理后,破骨细胞骨吸收几乎完全被抑制[1]。 |
In Vivo | 穿心莲内酯(5或30 mg/kg)治疗可降低LPS诱导的骨丢失程度。此外,与LPS治疗相比,穿心莲内酯略微增加BMD和皮质厚度。组织学检查证实了穿心莲内酯对LPS诱导的骨丢失的保护作用。 LPS注射导致炎性骨侵蚀和TRAP阳性破骨细胞数量增加[1]。 |
Cell Experiment | 穿心莲内酯对细胞增殖的影响用CCK-8测定。将BMM以每孔3×103个细胞的密度接种在96孔板中,一式三份。二十四小时后,用增加浓度的穿心莲内酯(0,2.5,5,10或20μM)处理细胞2天。接下来,向每个孔中加入10μLCCK-8,然后将板在37℃下再孵育2小时。然后用ELX800吸光度酶标仪在450nm波长(650nm参比)下测量光密度(OD)。计算细胞活力[1]。 |
Animal Experiment | 将小鼠[1] C57BL/6小鼠(8周龄)分成四组,每组七只小鼠。在注射LPS(5μg/ g体重)前1天,用穿心莲内酯(5或30mg/kg体重)或PBS作为对照腹膜内注射小鼠。每隔一天腹膜内注射穿心莲内酯或PBS,持续8天。在第一天和第四天腹膜内注射LPS。在初始LPS注射后8天杀死所有小鼠,并且用高分辨率微CT以9μm的分辨率扫描所有动物的左股骨。 |
Kinase Experiment | 进行体外破骨细胞生成测定以检查穿心莲内酯对破骨细胞分化的影响。制备骨髓巨噬细胞(BMM)细胞。简言之,将从6周龄C57/BL6小鼠的股骨和胫骨中提取的细胞在完全细胞培养基和30ng/mL M-CSF中在T-75cm 2培养瓶中孵育用于增殖。当更换培养基时,洗涤细胞以消耗残留的基质细胞。达到90%汇合后,用PBS洗涤细胞三次并用胰蛋白酶消化30分钟以收获BMM。粘附在培养皿底部的细胞被归类为BMM;将这些BMM以每孔8×103个细胞的密度接种在96孔板中,一式三份,并在含有5%CO 2的潮湿培养箱中于37℃温育24小时。然后用各种浓度的穿心莲内酯(0,2.5,5或10μM)加M-CSF(30ng/mL)和RANKL(50ng/mL)处理细胞。 5天后,固定细胞并染色以抗酒石酸酸性磷酸酶(TRAP)活性。具有超过五个细胞核的TRAP阳性多核细胞被计为破骨细胞[1]。 |
Data Literature Source | [1]. Zhai ZJ,et al. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo. Br J Pharmacol. 2014 Feb;171(3):663-75 |
Unit | Bottle |
Specification | 50mg 10mM*1mL in DMSO 100mg 500mg |
是一种 NF-κB 抑制剂,通过共价修饰内皮细胞中 p50 的半胱氨酸残基而抑制 NF-κB 活化,而不影响 IκBα 降解或 p50/p65 核易位。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Screening cyclooxygenase-2 inhibitors from Andrographis paniculata to treat inflammation based on bio-affinity ultrafiltration coupled with UPLC-Q-TOF-MS.
Click to check >>Author:Jiao J, Yang Y, Wu Z, Li B, Zheng Q, Wei S, Wang Y
IF:2.7660
Publish_to:Fitoterapia
PMID:31319108
Self-Assembled Casein Nanoparticles Loading Triptolide for the Enhancement of Oral Bioavailability
Click to check >>Author:Liu C .Jiang T T .Yuan Z X
IF:0.9600
Publish_to:Natural product communications
PMID: